Physician profile
Gerard Murphy
NPI 1104995414
$3,405.70
in general payments reported to CMS, 2019-2025
28 companies · $187 in 2025
The $187 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $429 · 2020: $596 · 2021: $599 · 2022: $601 · 2023: $637 · 2024: $355 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,179.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $603.99 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $386.22 | 2019-2025 | |
| Glaxosmithkline, LLC. | $320.52 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $266.08 | 2020-2025 | Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $221.33 | 2019-2022 | |
| Abbvie INC. | $155.29 | 2021-2025 | |
| Mylan Specialty L.P. | $150.17 | 2020-2024 | Yupelri |
| Lilly USA, LLC | $150.13 | 2019-2025 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $128.59 | 2019-2023 | Xarelto |
| Abbott Laboratories | $110.48 | 2021-2025 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $105.58 | 2021-2024 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $98.17 | 2022-2024 | Eliquis |
| Otsuka America Pharmaceutical, INC. | $85.09 | 2021-2023 | Rexulti |
| Merck Sharp & Dohme LLC | $83.51 | 2019-2021 | |
| Amgen INC. | $78.56 | 2023-2024 | Otezla, Repatha |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $70.80 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $60.04 | 2019-2021 | |
| Genentech USA, INC. | $59.28 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $55.04 | 2022-2023 | |
| Neurocrine Biosciences, INC. | $39.22 | 2024 | Ingrezza |
| Bayer Healthcare Pharmaceuticals INC. | $33.47 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.11 | 2021-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $31.09 | 2021-2024 | Trintellix |
| Amarin Pharma, INC. | $17.18 | 2021 | |
| Astellas Pharma US INC | $16.76 | 2023 | Veozah |
| Allergan, INC. | $16.50 | 2020 | |
| Eisai INC. | $15.93 | 2021 | |
| Horizon Therapeutics Plc | $15.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerard Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.